<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;ff=20250128151121&amp;utm_campaign=pubmed-2&amp;fc=20230708114047
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;ff=20250128151121&amp;utm_campaign=pubmed-2&amp;fc=20230708114047" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Tue, 28 Jan 2025 20:11:22 +0000</lastbuilddate>
<pubDate>Tue, 28 Jan 2025 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Aspirin Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis Among Patients With Post-Thrombotic Syndrome: The Multicenter, Multinational, Randomized, Open-label ARIVA Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39874026/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250128151121&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The overall primary patency rate during the first six months following endovascular intervention for PTS was higher than expected and comparable between patients receiving aspirin combined with rivaroxaban and those receiving rivaroxaban alone.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Jan 28. doi: 10.1161/CIRCULATIONAHA.124.073050. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: In patients with post-thrombotic syndrome (PTS), stent recanalization of iliofemoral veins or the inferior vena cava can restore venous patency and improve functional outcomes. The risk of stent thrombosis is particularly increased during the first 6 months after intervention. The ARIVA trial tested whether daily aspirin 100 mg plus rivaroxaban 20 mg is superior to rivaroxaban 20 mg alone to prevent stent thrombosis within 6 months after stent placement for PTS.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In this multinational, academic, open-label, independently adjudicated trial, patients with a Villalta score >;4 points, a stenosis or occlusion of the inferior vena cava, iliac veins, or common femoral vein, successfully treated with venous stent placement, were randomized in a 1:1 fashion to the study groups. Key exclusion criteria included age &lt;18 or >;75 years, contraindications to anticoagulant use or acute venous thrombosis &lt;3 months. The primary efficacy outcome was the composite of no occlusion in the treated segment assessed at serial duplex ultrasound examinations or no re-intervention needed to maintain patency within 6 months. Secondary outcomes, including Villalta score, quality of life, and safety outcomes were also assessed. The study was registered in ClinicalTrials.gov (NCT04128956).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: From 2020 through 2022, 172 patients were screened, 169 randomized and 162 included in the full analysis set, receiving either aspirin plus rivaroxaban (n=80) or rivaroxaban alone (n=82) for six months. Mean age was 42.8 (standard deviation 14.7) years, 103 (60.9%) patients were women, 154 (97.5%) were Caucasian, and leg ulcers were present in 7% patients. The primary patency rate at six months was 94.8% vs. 92.4% (absolute risk difference: 2.4%; 95 %CI -13.6%; +18.0%), respectively. The mean decrease in the Villalta score for the affected leg (without ulcer) from baseline to 6 months was -6.7 (SD 4.4) and -7.0 (SD 5.2) points (p-value 0.36), respectively. There were no differences in other outcomes or quality of life at 6 months. No major bleeding occurred.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The overall primary patency rate during the first six months following endovascular intervention for PTS was higher than expected and comparable between patients receiving aspirin combined with rivaroxaban and those receiving rivaroxaban alone.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39874026/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250128151121&v=2.18.0.post9+e462414">39874026</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.073050>10.1161/CIRCULATIONAHA.124.073050</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39874026</guid>
<pubDate>Tue, 28 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Stefano Barco</dc:creator>
<dc:creator>Houman Jalaie</dc:creator>
<dc:creator>Tim Sebastian</dc:creator>
<dc:creator>Simon Wolf</dc:creator>
<dc:creator>Riccardo M Fumagalli</dc:creator>
<dc:creator>Michael Lichtenberg</dc:creator>
<dc:creator>Thomas Zeller</dc:creator>
<dc:creator>Christian Erbel</dc:creator>
<dc:creator>Oliver Schlager</dc:creator>
<dc:creator>Nils Kucher</dc:creator>
<dc:date>2025-01-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Aspirin Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis Among Patients With Post-Thrombotic Syndrome: The Multicenter, Multinational, Randomized, Open-label ARIVA Trial</dc:title>
<dc:identifier>pmid:39874026</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.073050</dc:identifier>
</item>
<item>
<title>Tricuspid regurgitation and outcomes in mitral valve transcatheter edge-to-edge repair</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39873695/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250128151121&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Post-procedural TR, but not baseline TR, was associated with outcomes after M-TEER. Careful TR assessment after the procedure would provide an optimal management for concomitant significant TR in patients undergoing M-TEER.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 28:ehae924. doi: 10.1093/eurheartj/ehae924. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: The association between periprocedural change in tricuspid regurgitation (TR) and outcomes in patients undergoing mitral transcatheter edge-to-edge repair (M-TEER) is unclear. This study aimed to examine the prognostic value of TR before and after M-TEER.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients in the OCEAN-Mitral registry were divided into four groups according to baseline and post-procedure echocardiographic assessments: no TR/no TR (no TR), no TR/significant TR (new-onset TR), significant TR/no TR (normalized TR), and significant TR/significant TR (residual TR) (all represents before/after M-TEER). Tricuspid regurgitation ≥ moderate was defined as significant. The primary outcome was cardiovascular death or heart failure hospitalization. Tricuspid regurgitation pressure gradient was also evaluated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The numbers of patients in each group were 2103 (no TR), 201 (new-onset TR), 504 (normalized TR), and 858 (residual TR). Baseline assessment for TR and TR pressure gradient was not associated with outcomes after M-TEER. In contrast, patients with new-onset TR had the highest adjusted risk for the primary outcome, followed by those with residual TR [compared with no TR as a reference, hazard ratio 1.83 (95% confidence interval: 1.39-2.40) for new-onset TR, 1.45 (1.23-1.72) for residual TR, and 0.82 (0.65-1.04) for normalized TR]. Similarly, from baseline to post-procedure, TR pressure gradient changes were associated with subsequent outcomes after M-TEER. New-onset and residual TR incidence was commonly associated with dilated tricuspid annulus diameter and atrial fibrillation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Post-procedural TR, but not baseline TR, was associated with outcomes after M-TEER. Careful TR assessment after the procedure would provide an optimal management for concomitant significant TR in patients undergoing M-TEER.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39873695/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250128151121&v=2.18.0.post9+e462414">39873695</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae924>10.1093/eurheartj/ehae924</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39873695</guid>
<pubDate>Tue, 28 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Shingo Matsumoto</dc:creator>
<dc:creator>Yohei Ohno</dc:creator>
<dc:creator>Satoshi Noda</dc:creator>
<dc:creator>Junichi Miyamoto</dc:creator>
<dc:creator>Norihiko Kamioka</dc:creator>
<dc:creator>Tsutomu Murakami</dc:creator>
<dc:creator>Yuji Ikari</dc:creator>
<dc:creator>Shunsuke Kubo</dc:creator>
<dc:creator>Yuki Izumi</dc:creator>
<dc:creator>Mike Saji</dc:creator>
<dc:creator>Masanori Yamamoto</dc:creator>
<dc:creator>Masahiko Asami</dc:creator>
<dc:creator>Yusuke Enta</dc:creator>
<dc:creator>Shinichi Shirai</dc:creator>
<dc:creator>Masaki Izumo</dc:creator>
<dc:creator>Shingo Mizuno</dc:creator>
<dc:creator>Yusuke Watanabe</dc:creator>
<dc:creator>Makoto Amaki</dc:creator>
<dc:creator>Kazuhisa Kodama</dc:creator>
<dc:creator>Junichi Yamaguchi</dc:creator>
<dc:creator>Toru Naganuma</dc:creator>
<dc:creator>Hiroki Bota</dc:creator>
<dc:creator>Masahiro Yamawaki</dc:creator>
<dc:creator>Hiroshi Ueno</dc:creator>
<dc:creator>Kazuki Mizutani</dc:creator>
<dc:creator>Daisuke Hachinohe</dc:creator>
<dc:creator>Toshiaki Otsuka</dc:creator>
<dc:creator>Kentaro Hayashida</dc:creator>
<dc:date>2025-01-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Tricuspid regurgitation and outcomes in mitral valve transcatheter edge-to-edge repair</dc:title>
<dc:identifier>pmid:39873695</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae924</dc:identifier>
</item>
<item>
<title>Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39873282/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250128151121&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In PARAGON-HF, in contrast with BMI, nearly every patient with HFpEF had central adiposity (as assessed by WHtR), and the risks of adverse heart failure events were more robustly related to WHtR. These data challenge the current reliance on BMI as an appropriate metric of adiposity, and they suggest that-rather than obesity-related HFpEF being regarded as a select HFpEF subgroup-central adiposity is a ubiquitous feature of HFpEF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 28:ehaf057. doi: 10.1093/eurheartj/ehaf057. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: An expansion of fat mass is an integral feature of patients with heart failure and preserved ejection fraction (HFpEF). While body mass index (BMI) is the most common anthropometric measure, a measure of central adiposity-the waist-to-height ratio (WHtR)-focuses on body fat content and distribution; is not distorted by bone or muscle mass, sex, or ethnicity; and may be particularly relevant in HFpEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The PARAGON-HF trial randomized 4796 patients with heart failure and ejection fraction ≥45% to valsartan or sacubitril/valsartan. The current work characterizes the association of BMI and WHtR with clinical features, outcomes, and the response to neprilysin inhibition.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: About half (49%) of the participants were considered obese by BMI (≥30 kg/m2), but nearly every patient (96%) had central adiposity (WHtR ≥0.5). Among patients who were not obese (BMI &lt;30 kg/m2), 860 (37%) had marked central adiposity (WHtR ≥0.6). Higher BMI and WHtR were both associated with higher risk of total heart failure hospitalizations, but as compared with BMI, WHtR was linearly associated with heart failure outcomes and identified a higher proportion of patients who had a particularly elevated risk (i.e., 30% or greater). An obesity-survival paradox (i.e., improved outcomes in those with greater adiposity) was apparent with BMI in unadjusted analyses, but it was not observed with WHtR. Although neprilysin inhibition appeared to have greater effects on heart failure outcomes in patients with higher BMI and WHtR, analyses of interaction with obesity metrics did not show significant heterogeneity across the range of values for adiposity.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In PARAGON-HF, in contrast with BMI, nearly every patient with HFpEF had central adiposity (as assessed by WHtR), and the risks of adverse heart failure events were more robustly related to WHtR. These data challenge the current reliance on BMI as an appropriate metric of adiposity, and they suggest that-rather than obesity-related HFpEF being regarded as a select HFpEF subgroup-central adiposity is a ubiquitous feature of HFpEF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39873282/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250128151121&v=2.18.0.post9+e462414">39873282</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf057>10.1093/eurheartj/ehaf057</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39873282</guid>
<pubDate>Tue, 28 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Alexander Peikert</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Ian J Kulac</dc:creator>
<dc:creator>Sheldon Litwin</dc:creator>
<dc:creator>Michael Zile</dc:creator>
<dc:creator>Akshay S Desai</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>Jawad H Butt</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Felipe Martinez</dc:creator>
<dc:creator>Dirk J Van Veldhuisen</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Jean Rouleau</dc:creator>
<dc:creator>Martin Lefkowitz</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>Milton Packer</dc:creator>
<dc:date>2025-01-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial</dc:title>
<dc:identifier>pmid:39873282</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf057</dc:identifier>
</item>
<item>
<title>Prevent peripheral arterial disease and remain alive!</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39873235/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250128151121&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 28:ehae934. doi: 10.1093/eurheartj/ehae934. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39873235/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250128151121&v=2.18.0.post9+e462414">39873235</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae934>10.1093/eurheartj/ehae934</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39873235</guid>
<pubDate>Tue, 28 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Christine Espinola-Klein</dc:creator>
<dc:date>2025-01-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Prevent peripheral arterial disease and remain alive!</dc:title>
<dc:identifier>pmid:39873235</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae934</dc:identifier>
</item>
<item>
<title>Bromocriptine in the treatment of peripartum cardiomyopathy: is it ready for prime time?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39873231/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250128151121&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 28:ehae875. doi: 10.1093/eurheartj/ehae875. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39873231/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250128151121&v=2.18.0.post9+e462414">39873231</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae875>10.1093/eurheartj/ehae875</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39873231</guid>
<pubDate>Tue, 28 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Uri Elkayam</dc:creator>
<dc:date>2025-01-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Bromocriptine in the treatment of peripartum cardiomyopathy: is it ready for prime time?</dc:title>
<dc:identifier>pmid:39873231</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae875</dc:identifier>
</item>
<item>
<title>CCN5 suppresses injury-induced vascular restenosis by inhibiting smooth muscle cell proliferation and facilitating endothelial repair via thymosin β4 and Cd9 pathway</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39873228/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250128151121&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: CCN5 exerts a dual protective effect on ISR by inhibiting VSMC proliferation and facilitating EC repair. CCN5rp-coated stent might be promising in the prevention of ISR after PCI.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 28:ehae911. doi: 10.1093/eurheartj/ehae911. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Members of the CCN matricellular protein family are crucial in various biological processes. This study aimed to characterize vascular cell-specific effects of CCN5 on neointimal formation and its role in preventing in-stent restenosis (ISR) after percutaneous coronary intervention (PCI).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Stent-implanted porcine coronary artery RNA-seq and mouse injury-induced femoral artery neointima single-cell RNA sequencing were performed. Plasma CCN5 levels were measured by enzyme-linked immunosorbent assay. Endothelial cell (EC)- and vascular smooth muscle cell (VSMC)-specific CCN5 loss-of-function and gain-of-function mice were generated. Mass spectrometry and co-immunoprecipitation were conducted to identify CCN5 interacting proteins. Additionally, CCN5 recombinant protein (CCN5rp)-coated stents were deployed to evaluate its anti-ISR effects in a porcine model.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Plasma CCN5 levels were significantly reduced and correlated closely with the degree of restenosis in ISR patients. CCN5 expression was significantly decreased in VSMCs of stent-implanted porcine coronary segments and injured mouse femoral arteries, especially in synthetic VSMCs. In contrast, elevated CCN5 expression was observed in regenerating ECs of injured vessels. Endothelial cell- and VSMC-specific CCN5 deletion mice exhibited exacerbation of injury-induced neointimal hyperplasia, while CCN5 gain-of-function alleviated neointimal formation. Mechanistic studies identified thymosin β4 (Tβ4) as a CCN5 interacting protein in ECs and EC-CCN5 promoted injury repair through Tβ4 cleavage product Ac-SDKP. Also, CCN5rp promoted EC repair to suppress neointimal hyperplasia via interaction with Cd9 extracellular domain. Moreover, implantation with CCN5rp-coated stent significantly increased stent strut coverage with ECs, which suppressed neointimal formation and ultimately alleviated ISR.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: CCN5 exerts a dual protective effect on ISR by inhibiting VSMC proliferation and facilitating EC repair. CCN5rp-coated stent might be promising in the prevention of ISR after PCI.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39873228/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250128151121&v=2.18.0.post9+e462414">39873228</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae911>10.1093/eurheartj/ehae911</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39873228</guid>
<pubDate>Tue, 28 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Qi Zhang</dc:creator>
<dc:creator>Hongda Li</dc:creator>
<dc:creator>Tao Zhuang</dc:creator>
<dc:creator>Lehua Xu</dc:creator>
<dc:creator>Wenrun Wu</dc:creator>
<dc:creator>Jingjiang Pi</dc:creator>
<dc:creator>Pengxiong Zhu</dc:creator>
<dc:creator>Liang Geng</dc:creator>
<dc:creator>Yunhao Duan</dc:creator>
<dc:creator>Jianfei Xu</dc:creator>
<dc:creator>Jinnan Yue</dc:creator>
<dc:creator>Xiuxiang Liu</dc:creator>
<dc:creator>Chenlong He</dc:creator>
<dc:creator>Xiaoli Chen</dc:creator>
<dc:creator>Chengchao Ruan</dc:creator>
<dc:creator>Shougang Zhuang</dc:creator>
<dc:creator>Zhongmin Liu</dc:creator>
<dc:creator>Yilong Wang</dc:creator>
<dc:creator>Lin Zhang</dc:creator>
<dc:creator>Jie Liu</dc:creator>
<dc:creator>Yuzhen Zhang</dc:creator>
<dc:date>2025-01-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>CCN5 suppresses injury-induced vascular restenosis by inhibiting smooth muscle cell proliferation and facilitating endothelial repair via thymosin β4 and Cd9 pathway</dc:title>
<dc:identifier>pmid:39873228</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae911</dc:identifier>
</item>
<item>
<title>The year in cardiovascular medicine 2024: the top 10 papers in cardio-oncology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39873207/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250128151121&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 28:ehaf019. doi: 10.1093/eurheartj/ehaf019. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39873207/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250128151121&v=2.18.0.post9+e462414">39873207</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf019>10.1093/eurheartj/ehaf019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39873207</guid>
<pubDate>Tue, 28 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Joerg Herrmann</dc:creator>
<dc:creator>Teresa López-Fernández</dc:creator>
<dc:creator>Alexander R Lyon</dc:creator>
<dc:date>2025-01-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The year in cardiovascular medicine 2024: the top 10 papers in cardio-oncology</dc:title>
<dc:identifier>pmid:39873207</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf019</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: Is left atrial appendage closure a safe and effective OPTION after ablation for atrial fibrillation?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39871755/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250128151121&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 28:ehae922. doi: 10.1093/eurheartj/ehae922. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39871755/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250128151121&v=2.18.0.post9+e462414">39871755</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae922>10.1093/eurheartj/ehae922</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39871755</guid>
<pubDate>Tue, 28 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Rocco Vergallo</dc:creator>
<dc:creator>Daniela Pedicino</dc:creator>
<dc:date>2025-01-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: Is left atrial appendage closure a safe and effective OPTION after ablation for atrial fibrillation?</dc:title>
<dc:identifier>pmid:39871755</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae922</dc:identifier>
</item>
<item>
<title>Cardiorespiratory Fitness Assessment in Stem Cell Transplant Recipients: Getting to the Heart of the Problem</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39869673/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250128151121&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Jan 28;151(4):309-311. doi: 10.1161/CIRCULATIONAHA.124.072547. Epub 2025 Jan 27.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39869673/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250128151121&v=2.18.0.post9+e462414">39869673</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072547>10.1161/CIRCULATIONAHA.124.072547</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39869673</guid>
<pubDate>Mon, 27 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Justin M Canada</dc:creator>
<dc:date>2025-01-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Cardiorespiratory Fitness Assessment in Stem Cell Transplant Recipients: Getting to the Heart of the Problem</dc:title>
<dc:identifier>pmid:39869673</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072547</dc:identifier>
</item>
<item>
<title>SLICE-CEA CardioLink-8: A Randomized Trial of Evolocumab on Carotid Artery Atherosclerotic Plaque Characteristics in Asymptomatic High-Risk Carotid Stenosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39869672/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250128151121&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Jan 28;151(4):351-355. doi: 10.1161/CIRCULATIONAHA.124.072285. Epub 2025 Jan 27.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39869672/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250128151121&v=2.18.0.post9+e462414">39869672</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072285>10.1161/CIRCULATIONAHA.124.072285</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39869672</guid>
<pubDate>Mon, 27 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>C David Mazer</dc:creator>
<dc:creator>Alan R Moody</dc:creator>
<dc:creator>Hwee Teoh</dc:creator>
<dc:creator>Adrian Quan</dc:creator>
<dc:creator>Randi Elituv</dc:creator>
<dc:creator>Thayalasuthan Vivekanandan</dc:creator>
<dc:creator>Peiyu Li</dc:creator>
<dc:creator>Kevin E Thorpe</dc:creator>
<dc:creator>Myriam Lafreniere-Roula</dc:creator>
<dc:creator>Raj Verma</dc:creator>
<dc:creator>Michael Moroney</dc:creator>
<dc:creator>Jack H Casey</dc:creator>
<dc:creator>Navneet Singh</dc:creator>
<dc:creator>Aditya Bharatha</dc:creator>
<dc:creator>Rasha Mahmoud</dc:creator>
<dc:creator>Regis Manorajah</dc:creator>
<dc:creator>Andrew Jayarajah</dc:creator>
<dc:creator>Anish N Kapadia</dc:creator>
<dc:creator>Andrew D Dueck</dc:creator>
<dc:creator>Mohammed Al-Omran</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>Lawrence A Leiter</dc:creator>
<dc:creator>Subodh Verma</dc:creator>
<dc:date>2025-01-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>SLICE-CEA CardioLink-8: A Randomized Trial of Evolocumab on Carotid Artery Atherosclerotic Plaque Characteristics in Asymptomatic High-Risk Carotid Stenosis</dc:title>
<dc:identifier>pmid:39869672</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072285</dc:identifier>
</item>
<item>
<title>Kidney Decline Predicts Worse Heart Failure Outcomes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39869671/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250128151121&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Jan 28;151(4):348-350. doi: 10.1161/CIRCULATIONAHA.124.072099. Epub 2025 Jan 27.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39869671/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250128151121&v=2.18.0.post9+e462414">39869671</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072099>10.1161/CIRCULATIONAHA.124.072099</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39869671</guid>
<pubDate>Mon, 27 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Bridget M Kuehn</dc:creator>
<dc:date>2025-01-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Kidney Decline Predicts Worse Heart Failure Outcomes</dc:title>
<dc:identifier>pmid:39869671</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072099</dc:identifier>
</item>
<item>
<title>Response by Hoeper et al to Letter Regarding Article, "Randomized, Multicenter Study to Assess the Effects of Different Doses of Sildenafil on Mortality in Adults with Pulmonary Arterial Hypertension"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39869670/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250128151121&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Jan 28;151(4):e32. doi: 10.1161/CIRCULATIONAHA.124.072235. Epub 2025 Jan 27.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39869670/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250128151121&v=2.18.0.post9+e462414">39869670</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072235>10.1161/CIRCULATIONAHA.124.072235</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39869670</guid>
<pubDate>Mon, 27 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Marius M Hoeper</dc:creator>
<dc:creator>Scott Haughie</dc:creator>
<dc:creator>Tarek Hassan</dc:creator>
<dc:creator>Susanne Vogt</dc:creator>
<dc:creator>Sarah Hackley</dc:creator>
<dc:date>2025-01-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Response by Hoeper et al to Letter Regarding Article, "Randomized, Multicenter Study to Assess the Effects of Different Doses of Sildenafil on Mortality in Adults with Pulmonary Arterial Hypertension"</dc:title>
<dc:identifier>pmid:39869670</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072235</dc:identifier>
</item>
<item>
<title>Relatively Increased CO&lt;sub>;2&lt;/sub>; Delivered to the Brain From the Descending Aorta Leading to an Elevated Respiratory Rate Causing Differential Hypocapnia (RIDDLER or East-West Syndrome): New Pitfalls in Awake Peripheral V-A ECMO</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39869669/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250128151121&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Jan 28;151(4):289-291. doi: 10.1161/CIRCULATIONAHA.124.071524. Epub 2025 Jan 27.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39869669/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250128151121&v=2.18.0.post9+e462414">39869669</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071524>10.1161/CIRCULATIONAHA.124.071524</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39869669</guid>
<pubDate>Mon, 27 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Alex Rosenberg</dc:creator>
<dc:creator>Louit Thakuria</dc:creator>
<dc:creator>Christophe Vandenbriele</dc:creator>
<dc:date>2025-01-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Relatively Increased CO&lt;sub>;2&lt;/sub>; Delivered to the Brain From the Descending Aorta Leading to an Elevated Respiratory Rate Causing Differential Hypocapnia (RIDDLER or East-West Syndrome): New Pitfalls in Awake Peripheral V-A ECMO</dc:title>
<dc:identifier>pmid:39869669</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071524</dc:identifier>
</item>
<item>
<title>Letter by Yan et al Regarding Article, "Randomized, Multicenter Study to Assess the Effects of Different Doses of Sildenafil on Mortality in Adults With Pulmonary Arterial Hypertension"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39869668/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250128151121&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Jan 28;151(4):e31. doi: 10.1161/CIRCULATIONAHA.124.071712. Epub 2025 Jan 27.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39869668/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250128151121&v=2.18.0.post9+e462414">39869668</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071712>10.1161/CIRCULATIONAHA.124.071712</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39869668</guid>
<pubDate>Mon, 27 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Peijing Yan</dc:creator>
<dc:creator>Min Zhang</dc:creator>
<dc:creator>Yunshan Cao</dc:creator>
<dc:date>2025-01-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Yan et al Regarding Article, "Randomized, Multicenter Study to Assess the Effects of Different Doses of Sildenafil on Mortality in Adults With Pulmonary Arterial Hypertension"</dc:title>
<dc:identifier>pmid:39869668</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071712</dc:identifier>
</item>
<item>
<title>State of the Heart (and Brain) in 2025</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39866123/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250128151121&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Jan 27. doi: 10.1161/CIRCULATIONAHA.125.073826. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39866123/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250128151121&v=2.18.0.post9+e462414">39866123</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.125.073826>10.1161/CIRCULATIONAHA.125.073826</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39866123</guid>
<pubDate>Mon, 27 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Dhruv S Kazi</dc:creator>
<dc:date>2025-01-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>State of the Heart (and Brain) in 2025</dc:title>
<dc:identifier>pmid:39866123</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.125.073826</dc:identifier>
</item>
<item>
<title>2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39866113/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250128151121&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The Statistical Update represents a critical resource for the lay public, policymakers, media professionals, clinicians, health care administrators, researchers, health advocates, and others seeking the best available data on these factors and conditions.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Jan 27. doi: 10.1161/CIR.0000000000001303. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The American Heart Association (AHA), in conjunction with the National Institutes of Health, annually reports the most up-to-date statistics related to heart disease, stroke, and cardiovascular risk factors, including core health behaviors (smoking, physical activity, nutrition, sleep, and obesity) and health factors (cholesterol, blood pressure, glucose control, and metabolic syndrome) that contribute to cardiovascular health. The AHA Heart Disease and Stroke Statistical Update presents the latest data on a range of major clinical heart and circulatory disease conditions (including stroke, brain health, complications of pregnancy, kidney disease, congenital heart disease, rhythm disorders, sudden cardiac arrest, subclinical atherosclerosis, coronary heart disease, cardiomyopathy, heart failure, valvular disease, venous thromboembolism, and peripheral artery disease) and the associated outcomes (including quality of care, procedures, and economic costs).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The AHA, through its Epidemiology and Prevention Statistics Committee, continuously monitors and evaluates sources of data on heart disease and stroke in the United States and globally to provide the most current information available in the annual Statistical Update with review of published literature through the year before writing. The 2025 AHA Statistical Update is the product of a full year's worth of effort in 2024 by dedicated volunteer clinicians and scientists, committed government professionals, and AHA staff members. This year's edition includes a continued focus on health equity across several key domains and enhanced global data that reflect improved methods and incorporation of ≈3000 new data sources since last year's Statistical Update.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Each of the chapters in the Statistical Update focuses on a different topic related to heart disease and stroke statistics.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The Statistical Update represents a critical resource for the lay public, policymakers, media professionals, clinicians, health care administrators, researchers, health advocates, and others seeking the best available data on these factors and conditions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39866113/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250128151121&v=2.18.0.post9+e462414">39866113</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001303>10.1161/CIR.0000000000001303</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39866113</guid>
<pubDate>Mon, 27 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Seth S Martin</dc:creator>
<dc:creator>Aaron W Aday</dc:creator>
<dc:creator>Norrina B Allen</dc:creator>
<dc:creator>Zaid I Almarzooq</dc:creator>
<dc:creator>Cheryl A M Anderson</dc:creator>
<dc:creator>Pankaj Arora</dc:creator>
<dc:creator>Christy L Avery</dc:creator>
<dc:creator>Carissa M Baker-Smith</dc:creator>
<dc:creator>Nisha Bansal</dc:creator>
<dc:creator>Andrea Z Beaton</dc:creator>
<dc:creator>Yvonne Commodore-Mensah</dc:creator>
<dc:creator>Maria E Currie</dc:creator>
<dc:creator>Mitchell S V Elkind</dc:creator>
<dc:creator>Wenjun Fan</dc:creator>
<dc:creator>Giuliano Generoso</dc:creator>
<dc:creator>Bethany Barone Gibbs</dc:creator>
<dc:creator>Debra G Heard</dc:creator>
<dc:creator>Swapnil Hiremath</dc:creator>
<dc:creator>Michelle C Johansen</dc:creator>
<dc:creator>Dhruv S Kazi</dc:creator>
<dc:creator>Darae Ko</dc:creator>
<dc:creator>Michelle H Leppert</dc:creator>
<dc:creator>Jared W Magnani</dc:creator>
<dc:creator>Erin D Michos</dc:creator>
<dc:creator>Michael E Mussolino</dc:creator>
<dc:creator>Nisha I Parikh</dc:creator>
<dc:creator>Sarah M Perman</dc:creator>
<dc:creator>Mary Rezk-Hanna</dc:creator>
<dc:creator>Gregory A Roth</dc:creator>
<dc:creator>Nilay S Shah</dc:creator>
<dc:creator>Mellanie V Springer</dc:creator>
<dc:creator>Marie-Pierre St-Onge</dc:creator>
<dc:creator>Evan L Thacker</dc:creator>
<dc:creator>Sarah M Urbut</dc:creator>
<dc:creator>Harriette G C Van Spall</dc:creator>
<dc:creator>Jenifer H Voeks</dc:creator>
<dc:creator>Seamus P Whelton</dc:creator>
<dc:creator>Nathan D Wong</dc:creator>
<dc:creator>Sally S Wong</dc:creator>
<dc:creator>Kristine Yaffe</dc:creator>
<dc:creator>Latha P Palaniappan</dc:creator>
<dc:creator>American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Committee</dc:creator>
<dc:date>2025-01-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association</dc:title>
<dc:identifier>pmid:39866113</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001303</dc:identifier>
</item>
<item>
<title>Differential Associations of Cigar, Pipe, and Smokeless Tobacco Use Versus Combustible Cigarette Use With Subclinical Markers of Inflammation, Thrombosis, and Atherosclerosis: The Cross-Cohort Collaboration-Tobacco Working Group</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39866105/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250128151121&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Use of noncigarette tobacco products is linked to subclinical markers relevant to cardiovascular harm. Inflammatory markers, such as high-sensitivity C-reactive protein and interleukin-6, have the potential for assessing early cardiovascular risk from these products and aiding regulatory authorities in evaluating their associated risks.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Jan 27. doi: 10.1161/CIRCULATIONAHA.124.070852. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Understanding the association of tobacco product use with subclinical markers is essential in evaluating health effects to inform regulatory policy. This is particularly relevant for noncigarette products (eg, cigars, pipes, and smokeless tobacco), which have been understudied because of their low prevalence in individual cohort studies.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This cross-sectional study included 98 450 participants from the Cross-Cohort Collaboration-Tobacco data set. Associations between the use of tobacco products and subclinical markers (high-sensitivity C-reactive protein, interleukin-6, fibrinogen, D-dimer, coronary artery calcium, carotid intima-media thickness, carotid plaque, and ankle-brachial index) were evaluated. The analyses used multivariable linear and logistic regression models to examine current use status for each product, with additional analyses of "sole" and "exclusive" noncigarette use (versus never use of either cigarettes or a specific noncigarette tobacco). Sole use was defined as the current use of a given noncigarette tobacco without concurrent combustible cigarette use, whereas exclusive use was defined as current noncigarette tobacco use without any history of combustible cigarette use.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 20.0%, 3.0%, 0.8%, and 1.5% of participants were current cigarette, cigar, pipe, or smokeless tobacco users, respectively. Current cigarette use showed associations with higher levels of all markers compared with never cigarette use. Compared with the relevant reference group, current, sole, and exclusive cigar use was associated with 10% (95% CI, 1-20), 19% (95% CI, 12-26), and 11% (95% CI, 2-21) higher high-sensitivity C-reactive protein on the geometric mean scale. Similar associations were observed for pipe and smokeless tobacco use. For interleukin-6, we observed that sole cigar use was associated with a 15% (95% CI, 6-24) higher geometric mean level, whereas current, sole, and exclusive pipe use were associated with 22% to 32% (all <i>P</i> values &lt;0.05) higher levels compared with their respective reference groups. Fibrinogen levels were 2% to 6% higher (all <i>P</i> values &lt;0.05) among current users of cigars, pipes, and smokeless tobacco compared with their respective reference groups. Carotid plaque and carotid intima-media thickness were also moderately associated with noncigarette tobacco use.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Use of noncigarette tobacco products is linked to subclinical markers relevant to cardiovascular harm. Inflammatory markers, such as high-sensitivity C-reactive protein and interleukin-6, have the potential for assessing early cardiovascular risk from these products and aiding regulatory authorities in evaluating their associated risks.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39866105/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250128151121&v=2.18.0.post9+e462414">39866105</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070852>10.1161/CIRCULATIONAHA.124.070852</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39866105</guid>
<pubDate>Mon, 27 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Zhiqi Yao</dc:creator>
<dc:creator>Erfan Tasdighi</dc:creator>
<dc:creator>Zeina A Dardari</dc:creator>
<dc:creator>Kunal K Jha</dc:creator>
<dc:creator>Ngozi Osuji</dc:creator>
<dc:creator>Tanuja Rajan</dc:creator>
<dc:creator>Ellen Boakye</dc:creator>
<dc:creator>Carlos J Rodriguez</dc:creator>
<dc:creator>Kunihiro Matsushita</dc:creator>
<dc:creator>Eleanor M Simonsick</dc:creator>
<dc:creator>Joao A C Lima</dc:creator>
<dc:creator>Rachel Widome</dc:creator>
<dc:creator>Debbie L Cohen</dc:creator>
<dc:creator>Lawrence J Appel</dc:creator>
<dc:creator>Amit Khera</dc:creator>
<dc:creator>Michael E Hall</dc:creator>
<dc:creator>Suzanne Judd</dc:creator>
<dc:creator>Shelley A Cole</dc:creator>
<dc:creator>Ramachandran S Vasan</dc:creator>
<dc:creator>Emelia J Benjamin</dc:creator>
<dc:creator>Aruni Bhatnagar</dc:creator>
<dc:creator>Andrew P DeFilippis</dc:creator>
<dc:creator>Michael J Blaha</dc:creator>
<dc:date>2025-01-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Differential Associations of Cigar, Pipe, and Smokeless Tobacco Use Versus Combustible Cigarette Use With Subclinical Markers of Inflammation, Thrombosis, and Atherosclerosis: The Cross-Cohort Collaboration-Tobacco Working Group</dc:title>
<dc:identifier>pmid:39866105</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070852</dc:identifier>
</item>
<item>
<title>Mechanisms of memory-supporting neuronal dynamics in hippocampal area CA3</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39864437/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250128151121&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Jan 25:S0092-8674(25)00049-2. doi: 10.1016/j.cell.2025.01.020. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39864437/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250128151121&v=2.18.0.post9+e462414">39864437</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.01.020>10.1016/j.cell.2025.01.020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39864437</guid>
<pubDate>Sun, 26 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Yiding Li</dc:creator>
<dc:creator>John J Briguglio</dc:creator>
<dc:creator>Sandro Romani</dc:creator>
<dc:creator>Jeffrey C Magee</dc:creator>
<dc:date>2025-01-26</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Mechanisms of memory-supporting neuronal dynamics in hippocampal area CA3</dc:title>
<dc:identifier>pmid:39864437</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.01.020</dc:identifier>
</item>
<item>
<title>Ligand interaction landscape of transcription factors and essential enzymes in E. coli</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39862855/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250128151121&amp;v=2.18.0.post9+e462414
      <description>Knowledge of protein-metabolite interactions can enhance mechanistic understanding and chemical probing of biochemical processes, but the discovery of endogenous ligands remains challenging. Here, we combined rapid affinity purification with precision mass spectrometry and high-resolution molecular docking to precisely map the physical associations of 296 chemically diverse small-molecule metabolite ligands with 69 distinct essential enzymes and 45 transcription factors in the gram-negative...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Jan 22:S0092-8674(25)00032-7. doi: 10.1016/j.cell.2025.01.003. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Knowledge of protein-metabolite interactions can enhance mechanistic understanding and chemical probing of biochemical processes, but the discovery of endogenous ligands remains challenging. Here, we combined rapid affinity purification with precision mass spectrometry and high-resolution molecular docking to precisely map the physical associations of 296 chemically diverse small-molecule metabolite ligands with 69 distinct essential enzymes and 45 transcription factors in the gram-negative bacterium Escherichia coli. We then conducted systematic metabolic pathway integration, pan-microbial evolutionary projections, and independent in-depth biophysical characterization experiments to define the functional significance of ligand interfaces. This effort revealed principles governing functional crosstalk on a network level, divergent patterns of binding pocket conservation, and scaffolds for designing selective chemical probes. This structurally resolved ligand interactome mapping pipeline can be scaled to illuminate the native small-molecule networks of complete cells and potentially entire multi-cellular communities.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39862855/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250128151121&v=2.18.0.post9+e462414">39862855</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.01.003>10.1016/j.cell.2025.01.003</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39862855</guid>
<pubDate>Sat, 25 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Hui Peng</dc:creator>
<dc:creator>Sergei Kotelnikov</dc:creator>
<dc:creator>Megan E Egbert</dc:creator>
<dc:creator>Shany Ofaim</dc:creator>
<dc:creator>Grant C Stevens</dc:creator>
<dc:creator>Sadhna Phanse</dc:creator>
<dc:creator>Tatiana Saccon</dc:creator>
<dc:creator>Mikhail Ignatov</dc:creator>
<dc:creator>Shubham Dutta</dc:creator>
<dc:creator>Zoe Istace</dc:creator>
<dc:creator>Mohamed Taha Moutaoufik</dc:creator>
<dc:creator>Hiroyuki Aoki</dc:creator>
<dc:creator>Neal Kewalramani</dc:creator>
<dc:creator>Jianxian Sun</dc:creator>
<dc:creator>Yufeng Gong</dc:creator>
<dc:creator>Dzmitry Padhorny</dc:creator>
<dc:creator>Gennady Poda</dc:creator>
<dc:creator>Andrey Alekseenko</dc:creator>
<dc:creator>Kathryn A Porter</dc:creator>
<dc:creator>George Jones</dc:creator>
<dc:creator>Irina Rodionova</dc:creator>
<dc:creator>Hongbo Guo</dc:creator>
<dc:creator>Oxana Pogoutse</dc:creator>
<dc:creator>Suprama Datta</dc:creator>
<dc:creator>Milton Saier</dc:creator>
<dc:creator>Mark Crovella</dc:creator>
<dc:creator>Sandor Vajda</dc:creator>
<dc:creator>Gabriel Moreno-Hagelsieb</dc:creator>
<dc:creator>John Parkinson</dc:creator>
<dc:creator>Daniel Segre</dc:creator>
<dc:creator>Mohan Babu</dc:creator>
<dc:creator>Dima Kozakov</dc:creator>
<dc:creator>Andrew Emili</dc:creator>
<dc:date>2025-01-25</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Ligand interaction landscape of transcription factors and essential enzymes in E. coli</dc:title>
<dc:identifier>pmid:39862855</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.01.003</dc:identifier>
</item>
<item>
<title>Designed mosaic nanoparticles enhance cross-reactive immune responses in mice</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39855201/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250128151121&amp;v=2.18.0.post9+e462414
      <description>Nanoparticle vaccines displaying combinations of SARS-like betacoronavirus (sarbecovirus) receptor-binding domains (RBDs) could protect against SARS-CoV-2 variants and spillover of zoonotic sarbecoviruses into humans. Using a computational approach, we designed variants of SARS-CoV-2 RBDs and selected 7 natural sarbecovirus RBDs, each predicted to fold properly and abrogate antibody responses to variable epitopes. RBDs were attached to 60-mer nanoparticles to make immunogens displaying two...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Jan 16:S0092-8674(24)01428-4. doi: 10.1016/j.cell.2024.12.015. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Nanoparticle vaccines displaying combinations of SARS-like betacoronavirus (sarbecovirus) receptor-binding domains (RBDs) could protect against SARS-CoV-2 variants and spillover of zoonotic sarbecoviruses into humans. Using a computational approach, we designed variants of SARS-CoV-2 RBDs and selected 7 natural sarbecovirus RBDs, each predicted to fold properly and abrogate antibody responses to variable epitopes. RBDs were attached to 60-mer nanoparticles to make immunogens displaying two (mosaic-2<sub>COM</sub>s), five (mosaic-5<sub>COM</sub>), or seven (mosaic-7<sub>COM</sub>) different RBDs for comparisons with mosaic-8b, which elicited cross-reactive antibodies and protected animals from sarbecovirus challenges. Naive and COVID-19 pre-vaccinated mice immunized with mosaic-7<sub>COM</sub> elicited antibodies targeting conserved RBD epitopes, and their sera exhibited higher binding and neutralization titers against sarbecoviruses than mosaic-8b. Mosaic-2<sub>COM</sub>s and mosaic-5<sub>COM</sub> elicited higher antibody potencies against some SARS-CoV-2 variants than mosaic-7<sub>COM</sub>. However, mosaic-7<sub>COM</sub> elicited more potent responses against zoonotic sarbecoviruses and highly mutated Omicrons, supporting its use to protect against SARS-CoV-2 variants and zoonotic sarbecoviruses.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39855201/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250128151121&v=2.18.0.post9+e462414">39855201</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.12.015>10.1016/j.cell.2024.12.015</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39855201</guid>
<pubDate>Fri, 24 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Eric Wang</dc:creator>
<dc:creator>Alexander A Cohen</dc:creator>
<dc:creator>Luis F Caldera</dc:creator>
<dc:creator>Jennifer R Keeffe</dc:creator>
<dc:creator>Annie V Rorick</dc:creator>
<dc:creator>Yusuf M Adia</dc:creator>
<dc:creator>Priyanthi N P Gnanapragasam</dc:creator>
<dc:creator>Pamela J Bjorkman</dc:creator>
<dc:creator>Arup K Chakraborty</dc:creator>
<dc:date>2025-01-24</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Designed mosaic nanoparticles enhance cross-reactive immune responses in mice</dc:title>
<dc:identifier>pmid:39855201</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.12.015</dc:identifier>
</item>
<item>
<title>A pair of LysM receptors mediates symbiosis and immunity discrimination in Marchantia</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39855200/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250128151121&amp;v=2.18.0.post9+e462414
      <description>Most land plants form symbioses with microbes to acquire nutrients but also must restrict infection by pathogens. Here, we show that a single pair of lysin-motif-containing receptor-like kinases, MpaLYR and MpaCERK1, mediates both immunity and symbiosis in the liverwort Marchantia paleacea. MpaLYR has a higher affinity for long-chain (CO7) versus short-chain chitin oligomers (CO4). Although both CO7 and CO4 can activate symbiosis-related genes, CO7 triggers stronger immune responses than CO4 in...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Jan 17:S0092-8674(24)01466-1. doi: 10.1016/j.cell.2024.12.024. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Most land plants form symbioses with microbes to acquire nutrients but also must restrict infection by pathogens. Here, we show that a single pair of lysin-motif-containing receptor-like kinases, MpaLYR and MpaCERK1, mediates both immunity and symbiosis in the liverwort Marchantia paleacea. MpaLYR has a higher affinity for long-chain (CO7) versus short-chain chitin oligomers (CO4). Although both CO7 and CO4 can activate symbiosis-related genes, CO7 triggers stronger immune responses than CO4 in a dosage-dependent manner. CO4 can inhibit CO7-induced strong immune responses, recapitulating the early response to inoculation with the symbiont arbuscular mycorrhizal fungi. We show that phosphate starvation of plants increases their production of strigolactone, which stimulates CO4/CO5 secretion from mycorrhizal fungi, thereby prioritizing symbiosis over immunity. Thus, a single pair of LysM receptors mediates dosage-dependent perception of different chitin oligomers to discern symbiotic and pathogenic microbes in M. paleacea, which may facilitate terrestrialization.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39855200/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250128151121&v=2.18.0.post9+e462414">39855200</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.12.024>10.1016/j.cell.2024.12.024</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39855200</guid>
<pubDate>Fri, 24 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Xinhang Tan</dc:creator>
<dc:creator>Dapeng Wang</dc:creator>
<dc:creator>Xiaowei Zhang</dc:creator>
<dc:creator>Shuang Zheng</dc:creator>
<dc:creator>Xiaojie Jia</dc:creator>
<dc:creator>Hui Liu</dc:creator>
<dc:creator>Zilin Liu</dc:creator>
<dc:creator>Hao Yang</dc:creator>
<dc:creator>Huiling Dai</dc:creator>
<dc:creator>Xi Chen</dc:creator>
<dc:creator>Zhixin Qian</dc:creator>
<dc:creator>Ran Wang</dc:creator>
<dc:creator>Miaolian Ma</dc:creator>
<dc:creator>Peng Zhang</dc:creator>
<dc:creator>Nan Yu</dc:creator>
<dc:creator>Ertao Wang</dc:creator>
<dc:date>2025-01-24</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A pair of LysM receptors mediates symbiosis and immunity discrimination in Marchantia</dc:title>
<dc:identifier>pmid:39855200</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.12.024</dc:identifier>
</item>





























</channel>
</rss>